News
CAMRF
71.00
NaN%
--
Camurus Increases Shares and Votes Following Employee Stock Option Exercise
TipRanks · 11/28 06:32
Camurus Announces Nomination Committee for AGM 2026
TipRanks · 11/13 06:34
Camurus AB Earnings Call: Growth Amid Challenges
TipRanks · 11/11 00:08
Camurus Reports Positive Phase 1b Results for Monthly Semaglutide Depot
TipRanks · 11/10 07:45
Camurus AB Reports Strong Q3 Growth Amid Revised Outlook
TipRanks · 11/07 05:11
Camurus AB (publ) reports Q3 results
Seeking Alpha · 11/06 17:47
Camurus AB Reports Strong Q3 2025 Financial Performance and Strategic Milestones
TipRanks · 11/06 06:35
Camurus Increases Shares and Votes Following Employee Stock Option Exercise
TipRanks · 09/30 05:33
Weekly Report: what happened at CAMRF last week (0908-0912)?
Weekly Report · 09/15 09:39
Weekly Report: what happened at CAMRF last week (0901-0905)?
Weekly Report · 09/08 09:41
Weekly Report: what happened at CAMRF last week (0825-0829)?
Weekly Report · 09/01 09:38
Weekly Report: what happened at CAMRF last week (0818-0822)?
Weekly Report · 08/25 09:42
Weekly Report: what happened at CAMRF last week (0811-0815)?
Weekly Report · 08/18 09:40
Weekly Report: what happened at CAMRF last week (0804-0808)?
Weekly Report · 08/11 09:42
Weekly Report: what happened at CAMRF last week (0728-0801)?
Weekly Report · 08/04 09:43
Camurus AB (CAMRF) Has a New Rating from William O’Neil
TipRanks · 07/30 20:37
Weekly Report: what happened at CAMRF last week (0721-0725)?
Weekly Report · 07/28 09:43
Weekly Report: what happened at CAMRF last week (0714-0718)?
Weekly Report · 07/21 09:40
Camurus AB Reports Strong Q2 2025 Financial Results
TipRanks · 07/18 03:58
Camurus Reports Robust Growth in Q2 2025
TipRanks · 07/17 05:37
More
Webull provides a variety of real-time CAMRF stock news. You can receive the latest news about Camurus Sweden through multiple platforms. This information may help you make smarter investment decisions.
About CAMRF
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.